Valneva SE
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. Its business combines marketed travel vaccines with a research pipeline of vaccine candidates, and it operates from France with listings in both Europe and the United States.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaMarketed vaccines sold for travel-related and preventive immunization needs.
Clinical-stage vaccine candidates targeting infectious diseases and unmet medical needs.
Vaccine development programs supported through collaborations and licensing agreements.
Internal and outsourced manufacturing activities supporting vaccine supply.
Asiakkaat
Valneva sells to travelers, physicians, clinics, distributors, and public-health procurement channels that need preventive vaccines for infectious diseases. Its commercial vaccines address routine travel and protection needs, while its development programs are built to serve larger public-health and partnering opportunities. The company also works with pharmaceutical collaborators on selected vaccine candidates.
Clinics, physicians, and distributors that buy vaccines used before international travel.
Government and institutional buyers that may purchase vaccines for disease prevention programs.
Partners that collaborate on or commercialize selected vaccine candidates such as Lyme disease programs.
Individuals receiving travel or preventive vaccines through healthcare providers.
Strategia
Valneva’s strategy is to build a specialty vaccine portfolio around products addressing unmet medical needs while expanding its commercial vaccine base. It uses commercial revenue to support advanced development programs, including partnered and wholly owned candidates, and emphasizes differentiated, first-, best- or only-in-class opportunities. The company also prioritizes resource allocation toward core business areas and key strategic projects.
Commercial revenue helps finance the pipeline and supports operating flexibility.
Pipeline candidates create future product opportunities and partnering value.
Specialized products with unmet-need focus can support pricing and market access.
Maantiede
Valneva is headquartered in France and references operations and investor communications from Lyon. Its commercial and development activities are international, reflecting vaccine markets that are regulated country by country and sold across travel and public-health channels. The company also reports listings on Nasdaq and Euronext Paris, underscoring access to both U.S. and European capital markets.
Riskit
Valneva faces typical vaccine-industry risks tied to clinical development, regulatory approval, manufacturing execution, and demand variability in travel-related products. Company-specific risks also include dependence on a small number of marketed products and on the success of partnered or late-stage candidates, which can materially affect future growth. Foreign-exchange movements, public-health demand swings, and execution of restructuring or capital actions can also affect results.
- Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Vaccine commercialization requires approvals and ongoing compliance in each market.
Kohdistuu: Multi-country vaccine launches
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Pipeline value depends on successful trials and regulatory outcomes.
Kohdistuu: Lyme disease and Shigella candidates
- Manufacturing and supply executionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Vaccines require stringent quality control and reliable production capacity.
Kohdistuu - Concentration in travel vaccinesVaikutus: KeskitasoTodennäköisyys: Korkea
A small commercial portfolio can be sensitive to demand swings and competition.
Kohdistuu: Proprietary travel vaccines
- Foreign exchange volatilityVaikutus: KeskitasoTodennäköisyys: Korkea
International operations create currency translation and transaction exposure.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätSales of vaccines and partnership income may be recognized at different points in time or upon milestones.
Vaikutus: Affects quarterly comparability and reported growth
Clinical assets may require impairment if programs fail or expectations change.
Vaikutus: Can materially change operating results
Warrants or other financing features may require mark-to-market accounting.
Vaikutus: Can create non-cash volatility
Travel vaccine demand can vary with booking and vaccination cycles.
Vaikutus: Quarterly revenue and margin comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
Sinovac Biotech, Ltd
SVA · Pharmaceutical Preparations
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Inventiva S.A.
IVA · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Zhengye Biotechnology Holding Ltd
ZYBT · Pharmaceutical Preparations
Zhengye Biotechnology Holding Ltd is a Cayman Islands holding company with operating activities centered in Jilin, China through its veterinary vaccine business.
Päivitetty: 28.9.2026